NCT06880328View on ClinicalTrials.gov

18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

November 7, 2018

Primary Completion Date

September 4, 2019

Study Completion Date

September 4, 2019

Conditions
Schizophrenia
Interventions
DRUG

Ralmitaront

Participants were given a once 150 mg daily dose of Ralmitaront orally during the 14 day treatment period.

OTHER

Radiolabeled PET tracer [18F]-DOPA

\[18 F\]-DOPA solution for injection is manufactured by the PET imaging centers according to specifications established for the tracer at the site. The injection will happen prior to the scan being done and will last for approximately 30 seconds.

DRUG

Placebo

Participants were given a daily dose of the placebo during the 14 day treatment period.

Trial Locations (4)

20877

CBH Health, Gaithersburg

63141

St Louis Clinical Trials, St Louis

90502

Collaborative Neuroscience Network Inc., Torrance

91206

Parexel California Clinical Trials Medical Group, Glendale

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT06880328 - 18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia | Biotech Hunter | Biotech Hunter